This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Peramivir intramuscular (IM)
BioCryst Pharmaceuticals, Inc.
Drug Names(s): Peramivir intramuscular (IM)
Description: Peramivir intramuscular (IM) formulation could be used to treat outpatients infected with either seasonal flu or more virulent strain with avian flu. Multiple animal studies have indicated that a single injection of peramivir are effective at preventing death in mice infected with various strains of influenza including the more virulent current strain with H5N1.
Neuraminidase is an enzyme essential for the influenza virus to replicate and infect its hosts. The enzyme neuraminidase is responsible for the release of particles from infected cells. These particles then spread the disease and may also assist in spreading the virus through the mucus allowing it to escape the host through a sneeze or a cough, and infect others.
Deal Structure: BioCryst Pharmaceuticals and Shionogi announced in March 2007 that they entered into an exclusive license agreement to develop and commercialize peramivir in Japan.
Under the terms of the agreement Shionogi will obtain rights to injectable formulations of peramivir in Japan in exchange for a $14 million up-front payment. BioCryst may also receive future clinical event milestone payments (up to $21 million) and commercial event milestone payments (up to $95 million) in addition to double digit (between 10 and 20% range) royalty payments on product sales of peramivir.
BioCryst retains all rights to commercialize peramivir in North America, Europe, and other countries outside of Japan and Korea.
Partners: Shionogi & Co. Ltd.
Peramivir intramuscular (IM) News
Pink Sheet Lilly manufacturing reinspections
Additional information available to subscribers only: